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Detection of micrometastases in the regional tumor-draining lymph nodes is critical for staging and prognosis in
melanoma patients. We applied a quantitative multiple-marker RT-PCR assay to improve the detection of occult
melanoma cells in the sentinel lymph node (SLN). From 139 patients with primary cutaneous melanoma who
underwent sentinel lymphadenectomy, a total of 235 SLN were assessed for Melan-A and tyrosinase expression by
real-time quantitative RT-PCR. Twenty-three patients (17%) were positive by histopathology and expressed mes-
senger RNA of one or two markers. Of the patients with histopathologically negative SLN 39 (28%) were reclassiﬁed
by positive RT-PCR. Patients were examined for tumor recurrences during a median follow-up period of 29 mo.
Tumor recurrences were demonstrated in eight patients (35%) with histopathologically positive SLN, in four pa-
tients (10%) with submicroscopic tumor cells detected exclusively by real-time RT-PCR, and in none of the patients
negative by both methods. The differences in recurrence rates were statistically significant (p¼ 0.01). These data
indicate that real-time quantitative RT-PCR for the detection of minimal residual melanoma in SLN improves the
prediction of disease-free survival.
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In early stages of primary cutaneous melanoma (American
Joint Committee on Cancer stages I and II), Breslow’s tumor
thickness was demonstrated to be the single most impor-
tant prognostic factor (Morton et al, 1993). With the devel-
opment of regional lymph node metastasis (American Joint
Committee on Cancer stage III), the 5-y survival rate de-
creases 40%. At this tumor stage prognostic factors of pri-
mary melanoma no longer contribute significantly to survival
prediction. The extent of nodal involvement is strongly as-
sociated with survival rates (Balch et al, 1996). Accurate
nodal staging is useful for guiding adjuvant therapy (Kirk-
wood, 1998). The technique of sentinel lymph node (SLN)
biopsy is based on the concept that it identifies the first
node to receive a cutaneous afferent lymphatic from the
primary tumor. If the SLN does not contain melanoma cells,
then the probability that a non-sentinel node in the draining
lymphatic basin contains melanoma cells is less than 1%
(Morton et al, 1992). Serial sectioning and immunohistology
(IH) using HMB-45 and S-100 antibodies improves the de-
tection of occult melanoma cells, compared with conven-
tional hematoxylin and eosin (HE) staining alone (Cochran
et al, 1984; Morton et al, 1992). More recently, the technique
of RT-PCR has been demonstrated to increase substantially
the sensitivity of tumor cell detection (Blaheta et al, 1999).
Using tyrosinase as messenger RNA (mRNA) marker SLN
were analyzed by nested RT-PCR in comparison with his-
topathology including IH. Tumor recurrences after a median
follow-up period of 19 mo were observed in 67% of patients
with histopathologically positive SLN, in 25% of patients
with submicroscopic tumor cells detected by RT-PCR
alone, and 6% of patients negative by both methods (Blah-
eta et al, 2000). Histological and RT-PCR status of the SLN
were demonstrated to be the only significant prognostic
factors for disease-free survival. The results of two other
studies equally demonstrated significant differences of
tumor relapse for the three groups of patients determined
by their SLN status (Shivers et al, 1998; Bostick et al, 1999).
The molecular assay based on nested PCR is designed
to detect approximately three melanoma cells in 107 lymph
node cells (Wang et al, 1994), but the question of whether
such minimal amounts of cancer cells are clinically impor-
tant remains controversial. We reasoned that in particular
for the patient group exclusively positive by RT-PCR, it
would be instructive to perform a quantitative RT-PCR anal-
ysis of tumor-associated gene expression. It is conceivable
that values of mRNA marker gene expression above a cer-
tain cut-off level may be a more powerful predictor of dis-
ease relapse than values below this cut-off. A single-step
real-time RT-PCR assay has recently been established for
accurate and reproducible quantitation of the melanoma-
associated tyrosinase and Melan-A mRNA (Abrahamsen
et al, 2004). In a prospective diagnostic study, we have de-
veloped a similar quantitative multiple marker RT-PCR that
uses tyrosinase and Melan-A mRNA expression to detect
occult melanoma cells in comparison with conventional IH
in SLN. In this study, the prognostic impact of the presence
of nodal melanoma micrometastases detected by real-time
Abbreviations: CI, confidence interval; HE, hematoxylin and eosin;
IH, immunohistology; mRNA, messenger RNA; SLN, sentinel lymph
node
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quantitative RT-PCR was evaluated. The question was ad-
dressed as to whether a patient group with a high risk for
developing melanoma recurrence and a favorable prognos-
tic group of patients with a low risk of relapse may be dis-
tinguished by quantitative RT-PCR.
Results
Real-time RT-PCR analysis of SLN A major disadvantage
of nested PCR is the high risk of false-positive results be-
cause of PCR artifacts and contamination, making this tech-
nique unsuitable for clinical diagnostics. We therefore
investigated whether a closed-tube real-time PCR would
be a practical approach to overcome these difficulties. Best
suited for our demands of fast and reliable real-time PCR,
we chose the LightCycler system. Absolute mRNA levels of
tyrosinase and Melan-A were determined in 235 SLN from a
total of 139 patients with primary cutaneous melanoma us-
ing real-time quantitative PCR. The sample collection and
preparation was modified for future automated settings. To
exclude samples with low mRNA yield, a cut-off level of
12,000 transcripts of b-actin per mL cDNA was implemented.
Detection of single transcripts is possible; we used, howev-
er, a concentration of 10 transcripts per 10 mL of cDNA as
cut-off for the detection of the melanoma-specific parame-
ters. Two housekeeping genes, b-actin and cyclophilin B,
were quantified as internal standards (see supplement). Re-
producibility and sensitivity of tumor cell detection were
tested as described in the supplement.
Tyrosinase and Melan-A expression are linked We per-
formed a quantitative comparison between Melan-A and
tyrosinase expression using identical lymph node samples.
There was a strict correlation between Melan-A and tyros-
inase transcript numbers (Spearman’s correlation coeffi-
cient (rs)¼ 0.94; 95% confidence interval (CI): 0.89–0.98).
The regression equation can be interpreted as having a
slope of 1.0 within the 95% CI (see supplement), thus yield-
ing a 2.2-fold (95% CI: 1.58–3.13) higher transcript number
for Melan-A than for tyrosinase. For comparison, lymph
nodes with occurrence of benign melanocytic nevus cells
contained between 1.9 and 552 transcripts per mL of Melan-
A and displayed ratios of Melan-A to tyrosinase expression
between 2.3 and 5.2. A sample from a clinically palpable
lymph node metastasis showed 25,892 Melan-A transcripts
per mL and a ratio of 1.9. Nevus cells as well as the lymph
node metastasis are not included.
Comparison of real-time RT-PCR with histopatholo-
gy We then compared mRNA levels with the classification
by histopathology. Of 25 SLN positive by HE staining, 21
were real-time PCR positive with a range of 1.2 to 73,714
Melan-A transcripts per mL (median 1466), whereas six of
nine SLN positive by IH but negative by HE staining were
real-time PCR positive ranging from 1.6 to 37 Melan-A
transcripts per mL (median 7.6). Thirty-two SLN negative by
histopathology (including IH) but real-time PCR positive
ranged from 1.0 to 1336 Melan-A transcripts per mL (median
4.0, Fig 1). Melan-A transcript numbers were significantly
different between the SLN groups defined by positive and
negative histopathology (po0.0001).
For the population of 139 consecutive patients with pri-
mary cutaneous melanoma in which SLN biopsy was per-
formed, the clinical and histopathologic characteristics are
given in the supplement. From these 139 patients, a total of
235 SLN, ranging from 1 to 6 (median 1, mean 1.70) per
patient, were investigated by standard histopathology in-
cluding immunohistochemistry and by real-time quantitative
RT-PCR using sets of PCR primers specific for tyrosinase as
well as Melan-A. Patients were grouped according to SLN
status as determined by routine histological analyses and
by real-time RT-PCR (Table 1). Twenty-three (17%) of 139
patients had a positive SLN biopsy result by histopatho-
logical evaluation and a positive biopsy result by tyrosinase
and or Melan-A real-time PCR (group 1). Only two patients
with nodal micrometastasis detected by histopathology
went undetected by real-time PCR (group 0). Thirty-nine
patients (28%) were identified with submicroscopic nodal
metastasis using real-time PCR (group 2) whereas 75 pa-
tients (54%) had negative SLN results by both assays
(group 3). During histopathological examination, special at-
tention was paid to the presence of nodal nevocytes that
may result in false-positive RT-PCR. Microfocal collections
of nevus cells were identified in the capsule of eight lymph
nodes from eight patients. These lymph nodes were ex-
cluded from the analysis.
Absence of correlation with Breslow’s tumor thick-
ness Patients with histopathologically proved metastatic
SLN had a significantly higher Breslow’s tumor thickness
(Table 1, group 1, median tumor thickness 2.40 mm) as com-
pared with patients with submicroscopic disease identified
Figure1
Quantification of Melan-A transcripts in comparison with histopa-
thology. Melan-A transcripts per mL of real-time RT-PCR from sentinel
lymph node (SLN) that were positive (triangles) or negative (circles) by
histopathology. SLN positive by hematoxylin and eosin (HE) staining
(n¼ 21) are shown as open triangles, SLN that were HE negative but
immunohistology positive (n¼ 6) are shown as solid triangles. Median
transcript numbers (horizontal lines) were 696 (8.2–3950) and 4.0 (2.2–
7.9) transcripts per mL (lower and upper quartiles in brackets) for his-
topathologically positive (n¼27) and negative (n¼ 32) SLN, respectively.
Melan-A transcript numbers were significantly different between the SLN
groups defined by positive and negative histopathology (po0.0001).
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exclusively by real-time RT-PCR (group 2, median tumor
thickness 1.20 mm, p¼ 0.0004). We did not, however, ob-
serve any significant difference between group 2 and pa-
tients with negative results by both assays (group 3, median
tumor thickness 1.30 mm, p¼0.96).
Real-time quantitative RT-PCR identiﬁes patients with
low risk for recurrent disease The incidence of recurrent
melanoma was evaluated for each patient group after a
median follow-up for the entire patient population of 29 mo.
During this period, 13 (9%) of the 139 patients developed
recurrent disease (Table 1). One of these patients was pos-
itive by immune histology but had a negative PCR result.
Eight of 23 (35%) patients with histopathologic proof of
nodal micrometastases and positive by RT-PCR (group 1)
relapsed and one of these patients died subsequently from
metastatic melanoma. Four (10%) of 39 patients who were
upstaged by the molecular assay (group 2) developed
tumor recurrences. Finally, none of the 75 patients whose
SLN biopsy results were negative by both techniques
(group 3) was found to have recurrent disease.
For patients whose melanoma recurred, the sites of the
first recurrence are summarized in the supplement. In gen-
eral, the distribution of recurrence sites in patients who were
histologically negative but RT-PCR positive (group 2) was
similar to that of the patients with positive histological re-
sults (group 1). Four patients from group 1 had recurrences
in the regional nodal basin, even though they underwent
complete node dissection. Two patients from group 2 had
recurrences regionally. They had not undergone a complete
dissection, since they were histologically negative.
Kaplan–Meier curves for relapse-free survival were sig-
nificantly related to the status of the SLN (Fig 2). Patients
whose SLN were histologically positive had significantly
lower relapse-free survival than patients exclusively positive
by RT-PCR (p¼0.009). Most importantly, among patients
with histologically negative SLN, those who were positive by
the molecular assay had significantly lower relapse-free
survival than those who were RT-PCR negative (p¼ 0.014).
Kaplan–Meier estimates after 48 mo for patients with his-
tologically positive SLN showed a probability of relapse-free
survival of 33%, for patients exclusively positive by RT-PCR
of 84%, and for patients negative by both diagnostic meth-
ods of 100% (Fig 2).
Discussion
The SLN concept implies that the first draining lymph nodes
are not bypassed in the draining site of a primary tumor.
This has been questioned by a report that patients showed
a negative sentinel node, whereas non-sentinel nodes were
positive by a sensitive nested tyrosinase PCR assay
(Lukowsky et al, 1999). It should be pointed out, however,
that only one of these patients had a non-sentinel node that
was also positive by IH. We did not directly address this
question. We did observe, however, that in 16 of 21 patients
with positive sentinel nodes, who were subsequently sub-
jected to lymph node dissection, the remaining regional
lymph nodes were negative by immunohistological analysis.
Five patients had only low frequencies of positive non-sen-
tinel nodes (one of four, one of nine, one of 25, two of 14,
and two of 27). In the few instances with a disseminated
pattern of metastasis in sentinel and non-sentinel nodes, up
to three lymph nodes positive by IH had to be excised al-
ready by sentinel biopsy. We conclude that immunohisto-
logical evaluation of sentinel nodes is highly predictive of
the presence of micrometastasis in the entire nodal region.
The results obtained with conventional histopathology
emphasize the clinical importance of detecting occult met-
astatic disease using more sensitive diagnostic techniques.
A highly sensitive nested RT-PCR assay for detection of
tyrosinase mRNA has previously been used as a marker for
screening of melanoma cells in sentinel nodes. In these
studies, recurrence rates were significantly higher in pa-
tients with submicroscopic tumor cells identified by RT-PCR
than in patients with negative RT-PCR (Shivers et al, 1998;
Blaheta et al, 2000). It has remained unknown, however, to
which extent disease-free survival is determined by minimal
numbers of tumor cells just detectable by the highly sen-
sitive nested RT-PCR assay as compared with larger RT-
PCR-positive micrometastases that just have eluded
immunohistological examination. Both extremes are includ-
ed in patients upstaged by the molecular assay and it would
Figure2
Kaplan–Meier disease-free survival. Probability of recurrence-free
survival for patients whose sentinel lymph node (SLN) were histopath-
ologically and real-time RT-PCR positive (Pathþ /PCRþ ), for patients
with histopathologically negative SLN who were reclassified by positive
PCR (Path/PCRþ ), and for patients with SLN negative by both as-
says (Path/PCR).












0 PathþPCR 2 (1%) 1.90 (1.40–2.40)c 1 (50%)
1 PathþPCRþ 23 (17%) 2.40 (1.41–5.28) 8 (35%)
2 PathPCRþ 39 (28%) 1.20 (0.93–1.98) 4 (10%)
3 PathPCR 75 (54%) 1.30 (1.00–1.60) 0 (0%)
Total 139 1.40 (1.00–2.24) 13 (9%)
HE, hematoxylin and eosin; IH, immunohistology; SLN, sentinel lymph
node.
aPathþ , HE, and/or IHþ ; Path, HE, and IH.
bLower and upper quartiles in brackets. See supplement.
cThe two observed values in brackets.
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be of great clinical relevance to determine the relative con-
tribution of each of these to recurrent disease. We therefore
subjected the SLN to a quantitative analysis of tyrosinase
and Melan-A mRNA expression.
Absolute mRNA levels were determined from 139 pa-
tients using real-time quantitative PCR. Of these, 17% were
positive by histopathology and real-time PCR, 28% were
negative by histopathology but positive by real-time PCR,
and 54% yielded negative results by both techniques. Pa-
tients with positive standard histology (HE staining) had
higher median Melan-A transcript numbers than patients
positive by serially sectioning and IH alone. The reliability of
real-time PCR has been demonstrated by comparison with
histopathology. Thus, only two of 25 patients positive by
histopathology failed to be detected by real-time PCR. In
both cases the corresponding SLN were negative by HE
staining and positive by IH alone. In both of these SLN only
single or oligocellular tumor deposits were microscopically
identified. In addition, heterogeneity of tumor antigen ex-
pression in micrometastases may lead to different results.
Thus, gp100 expression as determined by HMB-45
immunostaining shows intratumor heterogeneity whereas
staining intensity for tyrosinase appears to be more uniform
among tumor cells (Chen et al, 1995). In addition, S100 is
the most sensitive marker in comparison with tyrosinase
and Melan-A (de Vries et al, 2001).
To avoid false-positive detection of tyrosinase or Melan-
A mRNA in melanoma patients, and fortuitous expression of
these antigens in tumor-draining lymph nodes from control
patients with non-melanoma malignancies, we tested—with
negative result—a lymph node from a control patient with a
benign parotis tumor who had undergone surgery. In addi-
tion, non-SLN that were occasionally biopsied as negative
controls tested negative by RT-PCR. One possible source of
false-positive RT-PCR results, however, is the occurrence of
benign melanocytic nevus cells in tumor-draining lymph
nodes. We identified nevus cells in eight of 235 lymph nodes
(3.4%), above the reported nodal incidence of 1.2% but
similar to that in sentinel nodes (3.9%, Carson et al, 1996).
These nevus cell collections were morphologically charac-
terized by intracapsular location and immunoreactivity for
S-100 but not for HMB-45. These lymph nodes were not
included in our analysis.
Once patients develop regional node metastasis, histo-
pathologic parameters of the primary tumor such as Bre-
slow’s tumor thickness—the current basis for prognostic
classification of primary melanoma—was no longer signif-
icant in predicting disease-free survival. Accordingly, we
could not detect a significant correlation between transcript
levels of Melan-A or tyrosinase and tumor thickness (data
not shown). The clinical significance of submicroscopic
tumor cells is emphasized by the observation of significantly
increased recurrence rates in patients who were exclusively
positive by nested RT-PCR (Shivers et al, 1998; Bostick
et al, 1999; Blaheta et al, 2000). An important issue is
whether the highly sensitive nested RT-PCR assay overes-
timates the risk of recurrent disease. Using real-time RT-
PCR, we were able to detect tumor cells in the SLN from 12
of 13 patients whose melanoma recurred during a median
follow-up of 29 mo. Eight patients were positive by histo-
pathology and PCR; four patients were exclusively positive
by PCR. These results were obtained with an arbitrary cut-
off value of 1 Melan-A transcript per mL and among patients
with histologically negative results we observed a stati-
stically significant difference in disease-free survival
(p¼0.014) between those with a PCR-negative SLN and
those with a PCR-positive SLN. Our data obtained with
quantitative real-time RT-PCR indicate that by decreasing
the sensitivity we were able to increase the specificity of the
molecular assay. Determination of the clinical impact of
quantitative RT-PCR analysis of micrometastatic nodal dis-
ease will require a long-term follow-up in these patients.
Accurate staging of the SLN based on real-time RT-PCR
may provide the basis for a more effective clinical follow-up
schedule (Hofmann et al, 2002; Garbe et al, 2003). The in-
tensity of clinical and technical examinations can be reduced
during follow-up in the PCR-negative stage and may be in-
tensified in the PCR-positive stage. Moreover, adjuvant ther-
apy might improve survival for patients with PCR-positive
SLN (Kirkwood, 1998), and patients with PCR-negative SLN
may represent a low-risk group for disease relapse who may
be spared from the side effects of post-adjuvant therapy. We
conclude from these data that real-time PCR using the
LightCycler technology is a precise, rapid, and reliable meth-
od for detection and quantification of SLN micrometastasis.
It has the potential to more accurately reflect the risk of dis-
ease relapse and to define a subgroup of patients who may
benefit from aggressive surveillance for disease recurrence
and stratification into more appropriate adjuvant therapy.
Materials and Methods
Patients SLN biopsy was performed in 139 patients with primary
cutaneous melanoma (usually Breslow’s tumor thickness was
40.75 mm) from April 1999 to September 2002 at the Department
of Dermatology of the University Hospital Heidelberg. None of the
patients had clinical evidence of regional or metastatic disease
(American Joint Committee on Cancer stages I and II). The protocol
for the study was approved by the Ethics Committee of the Uni-
versity of Heidelberg. Patients gave their informed consent for all
aspects of the investigation according to the Declaration of Hel-
sinki principles.
SLN biopsy SLN biopsy was performed as described previously
(Kahle et al, 2000). SLN were harvested and cut in half through their
longitudinal axis.
Histopathologic examination One half of each SLN was fixed in
5% formaldehyde and sent for standard pathologic evaluation. It
was embedded in paraffin and the sections were examined with
HE staining. In all instances further sections were evaluated by IH
by use of a monoclonal antibody to HMB-45 (Hatta et al, 1998),
and antiserum to S-100 protein (Cochran et al, 1988). An SLN was
defined as positive by histopathology if tumor cells were identified
by HE staining and/or by immunostaining.
Sample collection for real-time PCR From the other half of each
SLN aliquots were collected in 1 mL of RNAlater (Ambion, Hunt-
ingdon, UK). After disruption of the tissue using a RiboLyser
(Thermo Hybaid, Heidelberg, Germany), mRNA was isolated with
the MagNA Pure LC robotic work station (Roche Applied Science,
Mannheim, Germany). cDNA was synthesized using AMV-RT and
oligo(dT) as primer (first strand cDNA synthesis kit, Roche Applied
Science). After termination of the cDNA synthesis, the reaction mix
was diluted to a final volume of 500 mL and stored at 201C until
PCR analysis.
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Real-time PCR Parameter-specific primer sets optimized for the
LightCycler (Roche Applied Science) were developed and kindly
provided by SEARCH-LC GmbH (Heidelberg, Germany). The PCR
was performed with the LightCycler-FastStart DNA Master SYBR
Green I kit (Roche Applied Science) according to the protocol
provided in the parameter-specific kits. cDNA input was normal-
ized by the average expression of the two housekeeping genes b-
actin and cyclophilin B. The data of two independent analyses for
each sample and parameter were averaged and presented as ad-
justed transcripts per mL cDNA. Multiplying this number by 3000
gives an estimate of the transcripts in an average biopsy.
Nodal nevi Capsular nevocytes might be a source for tyrosinase
or Melan-A mRNA detection by RT-PCR. All SLN sections were,
therefore, carefully examined for the presence of benign me-
lanocytes. Lymph node specimens with nevus cell aggregates
were excluded from our analysis.
Follow-up of patients Examination findings were judged true
positive when metastasis was confirmed by additional examination
techniques (e.g., histopathology or other imaging techniques) or by
the further course of the disease (documented growth of metas-
tasis during the following 6 mo). Conversely, if confirmation by
these criteria was lacking, findings were judged false positive.
Statistical analysis The analysis related to tumor thickness is
based on a non-parametric approach using median and quartiles
to describe location and scale parameters. Differences between
groups were assessed with the Mann–Whitney test. Strip-plots
were used to present the data graphically. Linear regression meth-
odology was used to gauge two PCR measurements that were
transformed on a log 10 base. The 95% CI for intercept and re-
gression coefficient b were also calculated. In case of inclusion of
the value 1 in the CI for b, the retransformed intercept was inter-
preted as the factor of change between both measurements. The
approach chosen also allowed to calculate 95% CI for the factor of
change. The correlation between two measurements was quanti-
fied by rs and its 95% CI. The calculations were performed using
SPLUS 2000 (MathSoft, Seattle, Washington) and Statxact (V.3,
Cytel Software Corporation, Boston, Massachusetts).
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